- Citi’s 11th Annual
Biotech Conference -
- 2016 Wells Fargo Healthcare Conference -
- Morgan Stanley Global Healthcare Conference -
- Webcasts Available Through Gilead Corporate Website -
FOSTER CITY, Calif.--(BUSINESS WIRE)--Sep. 6, 2016--
Gilead Sciences, Inc. (Nasdaq: GILD) today announced webcasts from three
upcoming investor conferences: Citi’s 11th Annual Biotech
Conference, the 2016 Wells Fargo Healthcare Conference and the Morgan
Stanley Global Healthcare Conference.
Kevin Young CBE, Gilead’s Chief Operating Officer and Norbert W.
Bischofberger, PhD, Gilead’s Executive Vice President, R&D and Chief
Scientific Officer, will participate in fireside chats at Citi’s 11th
Annual Biotech Conference on Wednesday, September 7 at 11:00 a.m.
Eastern Time (ET) and the 2016 Wells Fargo Healthcare Conference onThursday, September 8 at 9:55 a.m. ET, both taking place in Boston.
John F. Milligan, PhD, Gilead’s President and Chief Executive Officer,
will participate in a fireside chat at the Morgan Stanley Global
Healthcare Conference on Monday, September 12 at 9:20 a.m. ET in New
York.
The audio portion of the fireside chats will be accessible live through
the company’s Investors page at www.gilead.com/investors.
Please connect to the company’s website at least 15 minutes prior to the
start of the presentation to ensure adequate time for any software
download that may be required to listen to the webcast. The replay will
be available for 14 days following the presentation.
About Gilead
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases. Gilead has operations in more than 30
countries worldwide, with headquarters in Foster City, California.
For more information on Gilead Sciences, please visit the company’s
website at www.gilead.com,
follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs
at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160906006192/en/
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.Sung Lee, 650-524-7792Investor Relations
